Antiparasitic Drugs Market Report 2026

The antiparasitic drugs market size has grown strongly in recent years. It will grow from $25.58 billion in 2025 to $27.18 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of parasitic diseases, limited access to modern antiparasitic drugs in developing regions, traditional reliance on monotherapy drugs, rising veterinary care demand, lack of awareness about preventive measures.

The antiparasitic drugs market size is expected to see strong growth in the next few years. It will grow to $36.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growth in combination therapy adoption, advancements in precision medicine for parasitic infections, increasing focus on animal health and livestock protection, expansion of emerging markets, development of novel delivery systems for antiparasitic drugs. Major trends in the forecast period include rising incidence of parasitic infections, development of combination antiparasitic drugs, expansion of animal healthcare applications, growth of oral and injectable treatment preferences, emergence of novel antiparasitic agents.

The rising incidence of vector-borne diseases is expected to drive the growth of the antiparasitic drugs market in the coming years. Vector-borne diseases are infectious illnesses transmitted to humans or other animals through the bites of arthropods, primarily insects such as mosquitoes, ticks, and flies. Examples of vector-borne diseases include malaria, dengue, and yellow fever. Antiparasitic drugs play a crucial role in controlling these diseases by targeting and eliminating the parasites responsible. Commonly used antiparasitic drugs for malaria include chloroquine, doxycycline, and atovaquone-proguanil. For instance, in June 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that from January to June 2024, over 9.7 million dengue cases were recorded across the Americas, more than double the 4.6 million cases reported in 2023. In the United States, Puerto Rico reported 1,498 dengue cases, and 745 cases were identified among U.S. travelers returning from affected regions. Therefore, the increasing incidence of vector-borne diseases is supporting the growth of the antiparasitic drugs market.

Major companies in the antiparasitic drugs market are focusing on developing innovative products such as chewable veterinary treatments to improve ease of administration and enhance pet compliance. Chewable veterinary products are flavored, easy-to-administer tablets or treats designed to deliver medication to animals in a palatable and stress-free way. For instance, in April 2024, C.H. Boehringer Sohn AG and Co. KG, a Germany-based pharmaceutical company, launched NexGard Spectra to provide comprehensive parasite control. NexGard Spectra is a soft, flavorful chew that offers complete internal and external parasite protection for dogs, targeting fleas, ticks, heartworms, and various intestinal worms in a single monthly dose. It acts rapidly, killing fleas within four hours of administration and achieving over 99% effectiveness against multiple parasites shortly thereafter.

In July 2023, Bayer AG, a Germany-based multinational pharmaceutical and life sciences company, partnered with the Tropical and Public Health Institute (Swiss TPH) to develop innovative treatments against soil-transmitted helminths. The collaboration aims to advance the discovery and development of effective antiparasitic therapies, improve global access to treatment for affected populations, and strengthen research capabilities in tropical medicine, supporting sustainable health solutions in regions burdened by parasitic infections. The Tropical and Public Health Institute is a Switzerland-based research organization specializing in tropical and public health, with a focus on the prevention and control of infectious diseases.

Major companies operating in the antiparasitic drugs market are Pfizer Inc., Johnson & Johnson, Cadila Pharmaceuticals, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim Group, Zoetis Inc., Eisai Co. Ltd., Dr. Reddy's Laboratories, Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ceva Santé Animale S.A., Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Norbrook Laboratories Ltd., Mankind Pharma, Bimeda Inc., Indoco Remedies Ltd., ECO Animal Health, Lincoln Pharmaceuticals Ltd., Laboratorios Calier.

North America was the largest region in the antiparasitic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antiparasitic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antiparasitic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antiparasitic drugs market by raising the cost of imported active pharmaceutical ingredients and finished products, leading to higher production costs and pricing pressures. Segments such as anthelmintics and antiprotozoals, especially in injectable and oral forms, are most affected, with regions like North America and Europe facing supply chain disruptions. While tariffs have posed challenges for manufacturers, they also encourage local production and innovation in novel antiparasitic agents, offering potential long-term benefits for domestic markets.

The antiparasitic drugs market research report is one of a series of new reports that provides antiparasitic drugs market statistics, including antiparasitic drugs industry global market size, regional shares, competitors with a antiparasitic drugs market share, detailed antiparasitic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antiparasitic drugs industry. This antiparasitic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antiparasitic drugs are medications used to treat infections caused by different parasites that can affect humans, animals, or plants. Parasites are organisms that live on or inside a host and derive nutrients from it, often causing harm to the host. Antiparasitic drugs act by either killing these parasites or inhibiting their growth.

The main categories of antiparasitic drugs include anthelmintics, antiprotozoals, ectoparasiticides, and others. Anthelmintics are a class of drugs used to treat infections caused by parasitic worms. They function by either killing the parasites or preventing their growth and reproduction. The treatments include various types such as avermectins, benzimidazoles, pyrimidines, organophosphates, and imidazole thiazoles, which can be administered orally, by injection, or topically. These drugs are used by end users including hospitals, home care providers, specialty clinics, and others.

The antiparasitic drugs market consists of sales of antimalarial drugs, antiamoebic drugs, anti-trematode drugs and veterinary products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.